Oligodeoxynucleotide IMT504: Effects on Central Nervous System Repair Following Demyelination

Patricia A Mathieu1,2, Yim Rodriguez Sampertegui1,2, Fernanda Elias3

  • 1Facultad de Farmacia y Bioquímica, Departamento de Química Biológica, Universidad de Buenos Aires, Junín 956, C1113AAD, Buenos Aires, Argentina.

Molecular Neurobiology
|December 8, 2023
PubMed

Insights

Oligodeoxynucleotides (ODN) IMT504 show potential for treating demyelinating diseases like multiple sclerosis (MS). IMT504 regulates neuroinflammation and promotes oligodendrocyte regeneration in a cuprizone-induced demyelination model.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is an immune-mediated central nervous system (CNS) disease causing demyelination and inflammation.
  • The cuprizone (CPZ) model replicates MS-like lesions, inducing microgliosis and astrogliosis.
  • Oligodeoxynucleotides (ODN) with specific sequences show potential for remyelination.

Purpose of the Study:

  • To evaluate the remyelinating effects of ODN IMT504 in a rat CPZ-induced demyelination model.
  • To investigate IMT504's impact on neuroinflammation and oligodendrocyte progenitor cell (OPC) differentiation.

Main Methods:

  • CPZ administration to induce demyelination in rats.
  • Subcutaneous and intracranial administration of IMT504.
  • Immunohistochemistry and qPCR for analyzing cellular and molecular changes.
  • Evaluation of microgliosis, astrogliosis, OPCs, and mature oligodendrocytes.

Main Results:

  • IMT504 administration modulated the inflammatory response, accelerating the shift to an anti-inflammatory state.
  • IMT504 reduced overall microgliosis and specifically decreased phagocytic microglia.
  • IMT504 expanded the population of oligodendroglial progenitor cells (OPCs), leading to increased mature oligodendrocytes.
  • Both intracranial IMT504 injection and intravenous administration of IMT504-treated B lymphocytes yielded similar beneficial effects.

Conclusions:

  • IMT504 demonstrates potential in regulating neuroinflammation and promoting oligodendrogenesis.
  • These findings suggest IMT504 as a potential therapeutic agent for demyelinating diseases, including MS.
  • Further research into IMT504's mechanisms and efficacy is warranted for clinical translation.

Related Concept Videos